Over 100 pharmaceutical companies are competing to develop 120+ pipeline drugs for non-small cell lung cancer (NSCLC), with approximately 30+ drugs in late-stage development. The competitive landscape is driven by precision oncology advances, including next-generation targeted agents and immunotherapy combinations. Recent FDA approvals and designations highlight innovation in treating EGFR-mutated, ALK-positive, and other biomarker-selected NSCLC populations.

Anaveon, a late-stage preclinical biotech company focused on immune system reprogramming, announced the appointment of Thaminda Ramanayake as CEO. Ramanayake brings over 20 years of biopharmaceutical leadership experience, including roles at CureVac, Sanofi, BioMarin, and Amgen. He will lead Anaveon's advancement of its immunology pipeline toward clinical development, with ANV200 as the lead asset for T cell depletion in autoimmune and inflammatory diseases.

BioNTech shares plummeted 17.67% after the company issued weaker-than-expected 2026 revenue guidance of $2.2-$2.5 billion, citing normalized Covid vaccine sales. Co-founders Ugur Sahin and Ozlem Tureci plan to exit by end of 2026 to launch a new mRNA firm, while the company pivots toward capital-intensive oncology development. Despite maintaining a strong €16 billion cash position, investors are concerned about leadership continuity and the multi-year investment phase before oncology revenue contributions materialize.

Law firm Johnson Fistel is investigating BioNTech SE following the company's disclosure of declining COVID-19 vaccine demand, a net loss of €305 million in Q4 2025, and the planned departure of founders Uğur Şahin and Özlem Türeci by end of 2026. The investigation examines whether BioNTech complied with federal securities laws, with shareholders invited to join the investigation.

BioNTech shares fell 14.25% in premarket trading after co-founders Ugur Sahin and Özlem Türeci announced plans to transition to a new mRNA venture by end of 2026. The company also lowered 2026 sales guidance to $2.33-$2.68 billion due to declining COVID-19 vaccine demand, though it expects multiple late-stage oncology data readouts in 2026.

Moderna reached a $950 million settlement agreement with Arbutus Biopharma and Roivant's Genevant Sciences, resolving litigation related to its COVID-19 vaccine Spikevax and mRESVIA product. The settlement clears a major legal overhang, allowing the company to focus on future growth. Moderna expects to end 2026 with $4.5-5 billion in cash and aims for breakeven in 2028. The stock surged 8.85% in premarket trading as the settlement value was better than investors' worst-case fears.

Ten large-cap stocks were top performers last week, with First Majestic Silver leading gains at 25.23% following better-than-expected Q4 results. Other notable gainers include Moderna (19.68%) on FDA seasonal flu vaccine review news, Global Payments (19.52%) with strong Q4 earnings and a $2.6B buyback authorization, and Coinbase (11.32%). Companies like Omnicom, Garmin, Figma, and Pan American Silver also reported strong quarterly results and positive guidance.

BioNTech has filed a patent infringement lawsuit against Moderna, alleging that Moderna's next-generation COVID-19 vaccine mNEXSPIKE infringes on BioNTech's patented domain-based spike protein technology. BioNTech claims the technology targets specific domains of the spike protein rather than the full structure, enabling lower doses and improved storage stability. Moderna has not sought licensing rights or provided compensation, according to BioNTech. The lawsuit seeks monetary damages as Moderna's COVID-19 vaccine sales reached $1.168 billion through Q3 2025.

The global human vaccines market is projected to grow from USD 44.26 billion in 2025 to USD 62.45 billion by 2033, with a CAGR of 4.43%. Growth is driven by expanding immunization programs, technological advancements in mRNA and recombinant vaccines, and increased public health investments. mRNA vaccines and HPV vaccines are expected to grow fastest, while challenges include manufacturing complexity and regulatory compliance.

BioNTech announced the appointment of Kylie Jimenez as Chief People Officer effective March 1, 2026. Jimenez, a seasoned HR executive with over 20 years of experience at companies including Toyota, Johnson & Johnson, and Georg Fischer, will lead BioNTech's people strategy and organizational development as the company pursues its goal of becoming a multi-product oncology company by 2030.

BioNTech announced the appointment of Kylie Jimenez as Chief People Officer (CPO) effective March 1, 2026. Jimenez, who brings over 20 years of international HR experience from roles at Georg Fischer, Toyota, Johnson & Johnson, and General Mills, will lead BioNTech's personnel strategy and focus on talent acquisition, development, and fostering an inclusive corporate culture to support the company's goal of becoming a multi-product oncology company by 2030.

The global nanobiotechnology market is projected to grow from USD 172.81 billion in 2024 to USD 420.2 billion by 2034, driven by healthcare demand, R&D funding, and technological innovations in drug delivery and medical applications.